Table 1.
Characteristics of 15 993 Human Immunodeficiency Virus–Infected Adults Initiating an Integrase Strand Transfer Inhibitor–Based or Efavirenz-based Antiretroviral Therapy Regimen in the North American AIDS Cohort Collaboration on Research and Design (July 2009 to December 2016)
| Participants by Regimen, No. (%) | |||
|---|---|---|---|
| Characteristic | InSTI Baseda (n = 5824) | EFV Baseda (n = 10 169) | Overall (n = 15 993) |
| Age, median (IQR), y | 37.0 (28.0–48.0) | 41.0 (31.0–50.0) | 40.0 (30.0–50.0) |
| Female sex | 894 (15.3) | 1101 (10.8) | 1995 (12.5) |
| Black race | 2351 (40.4) | 4611 (45.3) | 6962 (43.5) |
| Hispanic ethnicity | 722 (12.4) | 1350 (13.3) | 2072 (13.0) |
| BMI, median (IQR)b | 25.1 (22.3–28.7) | 25.1 (22.3–28.6) | 25.1 (22.3–28.6) |
| Injection drug use | 566 (9.7) | 1033 (10.2) | 1599 (10.0) |
| Male-to-male sexual contact | 3209 (55.1) | 4523 (44.5) | 7732 (48.4) |
| Heterosexual behavior | 1349 (23.2) | 2030 (20.0) | 3379 (21.1) |
| Previous AIDS diagnosis | 480 (8.2) | 735 (7.2) | 1215 (7.6) |
| Hepatitis B | 214 (3.7) | 426 (4.2) | 640 (4.0) |
| Hepatitis C | 564 (9.7) | 1123 (11.0) | 1687 (10.6) |
| Previous depression diagnosis | 859 (14.8) | 1038 (10.2) | 1897 (11.9) |
| Previous anxiety diagnosis | 692 (11.9) | 727 (7.2) | 1419 (8.9) |
| Diabetes mellitus | 284 (4.9) | 545 (5.4) | 829 (5.2) |
| Hypertension | 817 (14.0) | 1792 (17.6) | 2609 (16.3) |
| Statin prescription | 340 (5.8) | 806 (7.9) | 1146 (7.2) |
| Elevated total cholesterol | 224 (3.9) | 508 (5.0) | 732 (4.6) |
| Baseline CD4 T-cell count, median (IQR), cells/μL | 349.0 (173.0–524.0) | 323.0 (178.0–461.0) | 332.0 (177.0–485.0) |
| Baseline viral load, median (IQR), copies/mL | 40 432.0 (8829.0–139 000.0) | 36 754.5 (7482.5–123 182.0) | 38 440.0 (8017.0–128 000.0) |
| Calendar year at initiation, median (IQR) | 2014 (2013–2015) | 2011 (2010–2012) | 2012 (2010–2014) |
Abbreviations: BMI, body mass index; EFV, efavirenz; InSTI, integrase strand transfer inhibitor; IQR, interquartile range.
aBoth regimens included the same backbone of tenofovir disoproxil fumarate (or tenofovir alafenamide) and emtricitabine.
bBMI calculated as weight in kilograms divided by height in meters squared.